252 related articles for article (PubMed ID: 23219934)
21. Novel formyl peptide receptor (FPR) agonists with pyridinone and pyrimidindione scaffolds that are potentially useful for the treatment of rheumatoid arthritis.
Crocetti L; Vergelli C; Guerrini G; Cantini N; Kirpotina LN; Schepetkin IA; Quinn MT; Parisio C; Di Cesare Mannelli L; Ghelardini C; Giovannoni MP
Bioorg Chem; 2020 Jul; 100():103880. PubMed ID: 32388428
[TBL] [Abstract][Full Text] [Related]
22. Synthesis of Five- and Six-Membered N-Phenylacetamido Substituted Heterocycles as Formyl Peptide Receptor Agonists.
Vergelli C; Schepetkin IA; Ciciani G; Cilibrizzi A; Crocetti L; Giovannoni MP; Guerrini G; Iacovone A; Kirpotina LN; Ye RD; Quinn MT
Drug Dev Res; 2017 Feb; 78(1):49-62. PubMed ID: 27859446
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, and biological evaluation of novel pyrrolidinone small-molecule Formyl peptide receptor 2 agonists.
Maciuszek M; Ortega-Gomez A; Maas SL; Garrido-Mesa J; Ferraro B; Perretti M; Merritt A; Nicolaes GAF; Soehnlein O; Chapman TM
Eur J Med Chem; 2021 Dec; 226():113805. PubMed ID: 34536667
[TBL] [Abstract][Full Text] [Related]
24. Mitocryptide-2: Identification of Its Minimum Structure for Specific Activation of FPR2-Possible Receptor Switching from FPR2 to FPR1 by Its Physiological C-terminal Cleavages.
Marutani T; Nishino K; Miyaji T; Kamada K; Ohura K; Kiso Y; Mukai H
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920954
[TBL] [Abstract][Full Text] [Related]
25. Structural determinants for the interaction of formyl peptide receptor 2 with peptide ligands.
He HQ; Troksa EL; Caltabiano G; Pardo L; Ye RD
J Biol Chem; 2014 Jan; 289(4):2295-306. PubMed ID: 24285541
[TBL] [Abstract][Full Text] [Related]
26. Identification of C-terminal phosphorylation sites of N-formyl peptide receptor-1 (FPR1) in human blood neutrophils.
Maaty WS; Lord CI; Gripentrog JM; Riesselman M; Keren-Aviram G; Liu T; Dratz EA; Bothner B; Jesaitis AJ
J Biol Chem; 2013 Sep; 288(38):27042-27058. PubMed ID: 23873933
[TBL] [Abstract][Full Text] [Related]
27. Structural changes of the ligand and of the receptor alters the receptor preference for neutrophil activating peptides starting with a formylmethionyl group.
Forsman H; Winther M; Gabl M; Skovbakke SL; Boulay F; Rabiet MJ; Dahlgren C
Biochim Biophys Acta; 2015 Jan; 1853(1):192-200. PubMed ID: 25447672
[TBL] [Abstract][Full Text] [Related]
28. Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Cheng N; Ye RD; Quinn MT
Biochem Pharmacol; 2014 Dec; 92(4):627-41. PubMed ID: 25450672
[TBL] [Abstract][Full Text] [Related]
29. Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential.
Maciuszek M; Cacace A; Brennan E; Godson C; Chapman TM
Eur J Med Chem; 2021 Mar; 213():113167. PubMed ID: 33486199
[TBL] [Abstract][Full Text] [Related]
30. Functional N-Formyl Peptide Receptor 2 (FPR2) Antagonists Based on the Ureidopropanamide Scaffold Have Potential To Protect Against Inflammation-Associated Oxidative Stress.
Stama ML; Lacivita E; Kirpotina LN; Niso M; Perrone R; Schepetkin IA; Quinn MT; Leopoldo M
ChemMedChem; 2017 Nov; 12(22):1839-1847. PubMed ID: 28922577
[TBL] [Abstract][Full Text] [Related]
31. Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Heart Failure.
Asahina Y; Wurtz NR; Arakawa K; Carson N; Fujii K; Fukuchi K; Garcia R; Hsu MY; Ishiyama J; Ito B; Kick E; Lupisella J; Matsushima S; Ohata K; Ostrowski J; Saito Y; Tsuda K; Villarreal F; Yamada H; Yamaoka T; Wexler R; Gordon D; Kohno Y
J Med Chem; 2020 Sep; 63(17):9003-9019. PubMed ID: 32407089
[TBL] [Abstract][Full Text] [Related]
32. Phosphoproteomic analysis sheds light on intracellular signaling cascades triggered by Formyl-Peptide Receptor 2.
Cattaneo F; Russo R; Castaldo M; Chambery A; Zollo C; Esposito G; Pedone PV; Ammendola R
Sci Rep; 2019 Nov; 9(1):17894. PubMed ID: 31784636
[TBL] [Abstract][Full Text] [Related]
33. Structural Determinants in the
Viklund M; Fredriksson J; Holdfeldt A; Lind S; Franzyk H; Dahlgren C; Sundqvist M; Forsman H
J Immunol; 2022 Apr; 208(7):1632-1641. PubMed ID: 35321878
[TBL] [Abstract][Full Text] [Related]
34. FPR2 signaling without β-arrestin recruitment alters the functional repertoire of neutrophils.
Gabl M; Holdfeldt A; Sundqvist M; Lomei J; Dahlgren C; Forsman H
Biochem Pharmacol; 2017 Dec; 145():114-122. PubMed ID: 28855087
[TBL] [Abstract][Full Text] [Related]
35. Molecular recognition of formylpeptides and diverse agonists by the formylpeptide receptors FPR1 and FPR2.
Zhuang Y; Wang L; Guo J; Sun D; Wang Y; Liu W; Xu HE; Zhang C
Nat Commun; 2022 Feb; 13(1):1054. PubMed ID: 35217703
[TBL] [Abstract][Full Text] [Related]
36. Formyl peptide derived lipopeptides disclose differences between the receptors in mouse and men and call the pepducin concept in question.
Winther M; Holdfeldt A; Sundqvist M; Rajabkhani Z; Gabl M; Bylund J; Dahlgren C; Forsman H
PLoS One; 2017; 12(9):e0185132. PubMed ID: 28934373
[TBL] [Abstract][Full Text] [Related]
37. The pyrazolone originally reported to be a formyl peptide receptor (FPR) 2/ALX-selective agonist is instead an FPR1 and FPR2/ALX dual agonist.
Sogawa Y; Shimizugawa A; Ohyama T; Maeda H; Hirahara K
J Pharmacol Sci; 2009 Nov; 111(3):317-21. PubMed ID: 19926937
[TBL] [Abstract][Full Text] [Related]
38. Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.
Schepetkin IA; Khlebnikov AI; Giovannoni MP; Kirpotina LN; Cilibrizzi A; Quinn MT
Curr Med Chem; 2014; 21(13):1478-504. PubMed ID: 24350845
[TBL] [Abstract][Full Text] [Related]
39. Structural characterization and inhibitory profile of formyl peptide receptor 2 selective peptides descending from a PIP2-binding domain of gelsolin.
Forsman H; Andréasson E; Karlsson J; Boulay F; Rabiet MJ; Dahlgren C
J Immunol; 2012 Jul; 189(2):629-37. PubMed ID: 22706076
[TBL] [Abstract][Full Text] [Related]
40. Structural and conformational studies of biased agonism through formyl peptide receptors.
Liao Q; Ye RD
Am J Physiol Cell Physiol; 2022 May; 322(5):C939-C947. PubMed ID: 35385323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
